Clinical trial sponsors working in oncology, hematology, IBD, infectious diseases, multiple sclerosis, and many rare diseases, rely on PSI’s guidance and experience, knowing we’re specialized and committed to delivering some of the most complex clinical projects in the industry.
Core Therapeutic Areas
Inflammatory Bowel Diseases (IBD)
Crohns’ Disease, Ulcerative Colitis, and other IBDs.
Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, and other Oncology indications.
Multiple Myeloma, Lymphomas, Leukemias, and other oncohematological indications.
Antimicrobial and Antifungal infections and other ID.
Multiple Sclerosis, Spasticity, and other neurological indications.
Hemophilia A & B, Von Willebrand Disease, Thrombocytopenia, Polycythemia Vera, Paroxysmal Nocturnal Hemoglobinuria (PNH).
By working closely with sites, building trust, and mitigating staff turnover, PSI was able to achieve FDA and EMA approval for nine studies over the...Read More
At a Glance: AI and ML-powered insights for your next trial A sponsor of a challenging breast cancer study needed to identify the optimal mix...Read More
At a Glance: FDA Approval in 4 Years Radiopharmaceutical clinical trials face a host of logistical challenges from startup through the clinical phase. A sponsor...Read More
At a Glance No trial is ever easy. But with the continued effects of the global pandemic and the war in Ukraine, the sponsor had...Read More
The PSI Advantage
PSI was flexible to meet the various challenges in clinical trial conduct. The rapid enrollment of patients and the quick study close out allowed on-time study completion.
Chief Medical Officer